Home » ProNAi Therapeutics Secures Orphan Drug Status for Lymphoma Drug
ProNAi Therapeutics Secures Orphan Drug Status for Lymphoma Drug
The FDA has awarded ProNAi Therapeutics orphan drug designation for its PNT2258 for treatment of diffuse large B-cell lymphoma.
ProNAi secured European Commission orphan drug status in August 2015 for the same indication.
The company currently is enrolling patients in two Phase 2 trials — “Wolverine,” and “Brighton” — for the treatment of relapsed and refractory DLBCL and Richter’s transformation, respectively.
Upcoming Events
-
07May
-
14May
-
23May
-
30May
-
21Oct